PROTECmo Study: Thrombocytopenia in VenoVenous ECMO Linked to High Bleeding Risk
Marta Velia Antonini, Hematologist, Perfusionist ECMO and NRP Specialist and Chair of the Normothermic Regional Perfusion EuroELSO Working Group, shared on X:
”Thrombocytopenia in VV ECMO? Highly prevalent in VV ECMO, and strongly associated with bleeding risk and reduced survival.
Platelet transfusions do not appear to significantly reduce bleeding risk: targeted prevention strategies needed!
- Adults with respiratory failure; baseline thrombocytopenia 27.9%, mild 14.7%, moderate 8.7%, severe 4.4%
- Thrombocytopenia in ECLS occurred at least once in 80.2%; mild 21.3%, moderate 32.2%, severe 26.7%
- Mild thrombocytopenia increased risk of bleedings by 61%; moderate and severe by 90%
- Risk for thrombocytopenia increased with ICU days prior to ECMO, postop admission, immunocompromised state, RRT, septic shock, low hemoglobin, circuit replacement.”
Read the full article in Critical Care.
Title: Incidence, kinetics, and clinical impact of thrombocytopenia in venovenous ECMO: insights from the multicenter observational PROTECMO study
Authors: Nina Buchtele, Kenichi Tanaka, Fabio Tuzzolino, Cara Agerstrand, Ali Ait Hssain, Jordi Riera, Peter Schellongowski, Matthieu Schmidt, Raj Ramanan, Martin Balik, Lars Mikael Broman, Nicolo Rizzitello, Konstanty Szułdrzyński, Whitney D. Gannon, Vito Fanelli, Brian Trethowan, Hergen Buscher, Huda Alfoudri, Marco Giani, Alain Combes, Giacomo Grasselli, Roberto Lorusso, Antonio Arcadipane, Daniel Brodie, Gennaro Martucci, PROTECMO Study group
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Aug 10, 2025, 02:59What's Hot in Clots – August 2025: Explore AF, PFO, STROKE, Antithrombotics and Cancer in One
-
Aug 8, 2025, 18:06Catch Up on Anticoagulation Forum Newsletter: Explore The Upcoming
-
Aug 8, 2025, 15:28Claudio Laudani: New Insights on P2Y12 Monotherapy in Antiplatelet Therapy
-
Aug 8, 2025, 11:59Wolfgang Miesbach on Frailty in Hemophilia: New Data Shows 3x Higher Risk
-
Aug 8, 2025, 06:26Francisco López Romero-Salazar Shares A Closer Look at ROTEM and Thrombin Generation Assays
-
Aug 10, 2025, 06:33CRH: Hereditary Combined Deficiency of the Vitamin K-Dependent Coagulation Factors
-
Aug 10, 2025, 06:01Karl Desch Shares Insights On a Recent Study on GWAS by Thibord et al
-
Aug 10, 2025, 04:39Sara García Barcenilla: High-Quality Care for People with Hemophilia and Congenital Bleeding Disorders
-
Aug 10, 2025, 01:12PROTECmo Study: Thrombocytopenia in VenoVenous ECMO Linked to High Bleeding Risk
-
Aug 9, 2025, 17:30Ayesha Butt: Role of Neutrophil Extracellular Traps in APS-Related Thrombosis
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 9, 2025, 15:36NBCA: Blood Clot Survivor Runs 2025 NYC Marathon with Team Stop the Clot
-
Aug 8, 2025, 18:33Hemophilia Alliance during Tennessee Hemophilia and Bleeding Disorders Foundation Annual Meeting 2025
-
Aug 7, 2025, 14:49JAMA+AI Conversations: David Rhew's Journey from Clinical Practice to Technology Leadership
-
Aug 6, 2025, 16:47My Clot Story: Birth Control and A Life-threatening Pulmonary Embolism
-
Aug 5, 2025, 17:59Heghine Khachatryan: Honored to Be Part of The WFH Regional Workshop 2025